Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Raloxifene

A selective oestrogen receptor modulator (SERM) approved in 1997 in the United States to prevent postmenopausal osteoporosis; since 2007 also to reduce the risk of invasive breast cancer. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?In the 1980s, when it was still called keoxifene, pharmacologist V. Craig Jordan saw in rats that it protected bone: some journals rejected his work, convinced that only oestrogens could do that.

Raloxifene HClGo to the active ingredient →
Raloxifene-d4Isotopically labelledRaloxifene-d4Cat. No. P-R006-032CAS 1185076-44-1

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.